NCT03449082View on ClinicalTrials.gov

Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

July 16, 2019

Study Completion Date

March 8, 2021

Conditions
Lateral Epicondylitis
Interventions
BIOLOGICAL

High concentration of Allo-ASC

10 million cells of Allo-ASC 0.5cc

BIOLOGICAL

Low concentration of Allo-ASC

1 million cells of Allo-ASC 0.5cc

DRUG

Fibrin glue

Fibrin glue 0.5cc

DRUG

Normal saline

Normal saline 0.5cc

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Korea Health Industry Development Institute

OTHER_GOV

lead

Seoul National University Hospital

OTHER

NCT03449082 - Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC) | Biotech Hunter | Biotech Hunter